CellCarta has a unique expertise in the proteomic analysis of biomarkers relevant to neurological disorders. As a member of the Biomarkers Consortium led by The Foundation for the National Institutes of Health (FNIH), CellCarta established robust mass spectrometry workflows for the analysis of cerebrospinal fluid (CSF) and developed a multiple reaction monitoring (MRM) panel used for the measurement of CSF protein biomarkers.
CellCarta worked with biopharmaceutical partners along with non-for-profit organizations such as the Michael J. Fox Foundation, leveraging its know-how for the study of important neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Schizophrenia, and Huntington’s disease.
In addition to our biomarker development work, we use our targeted MRM platform to provide an absolute quantification of biomarkers in clinical samples. MRM has increased in popularity as a tool for biomarker quantification due to its high sensitivity and specificity, and its multiplexing capabilities.
We also developed targeted MRM pharmacokinetics (PK) assays for the absolute quantification of biotherapeutics in various biological matrices such as brain tissue, CSF, and plasma.
Here are some examples of work we did in the field of neurosciences: